Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 301–400 of 987
Bensinger, W., Becker, P. S., Gooley, T. A., Chauncey, T. R., Maloney, D. G., Gopal, A. K., Green, D. J., Press, O. W., Lill, M., Ifthikharuddin, J. J., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.211 · Cited by 33
Barlogie, B., Bolejack, V., Schell, M. J., & Crowley, J. J. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1130-y · Cited by 38
Hematopoietic cell transplantation: progress and obstacles
Devetten, M. P., & Armitage, J. O. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm064 · Cited by 39
“particular for patients who achieve a suboptimal response to the first transplant procedure [65].”
BackgroundStem cell transplantation in multiple myeloma (0, 1, or 2)
Harousseau, J. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000152978.32304.37 · Cited by 34
Self-citationDispenzieri, A. A., Wiseman, G. A., Lacy, M. Q., Hayman, S. R., Kumar, S. K., Buadi, F. K., Dingli, D., Laumann, K. M., Allred, J., Geyer, S. M., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21696 · Cited by 35
Martino, M. V., Tripepi, G. L., Messina, G., Vincelli, I. D., Console, G., Recchia, A. G., Gentile, M., Molica, S., & Morabito, F. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.94 · Cited by 32
Du, J., Wei, R., Jiang, S., Jiang, H., Li, L., Qiang, W., He, H., Shi, L., Ma, Q., Yu, K., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26583 · Cited by 36
“1) was used to predict the cell type using the reference database Human Primary Cell Atlas Data.(16,17) Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and Reactome(18,19) functions were annotated using the R package cluster Profiler,(20) and all downstream analysis was performed in R 3.”
MethodInfluentialRamzi, M., Zakerinia, M., Nourani, H., Dehghani, M., Vojdani, R., & Haghighinejad, H. (2011) · Clinical Transplantation · doi:10.1111/j.1399-0012.2011.01432.x · Cited by 36
Nazha, A., Cook, R., Vogl, D. T., Mangan, P. A., Gardler, M., Hummel, K., Cunningham, K., Luger, S. M., Porter, D., Schuster, S. J., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.63 · Cited by 36
The Arkansas approach to therapy of patients with multiple myeloma
Barlogie, B., Anaissie, E. J., van Rhee, F., Pineda‐Roman, M., Zangari, M., Shaughnessy, J. D., Epstein, J., & Crowley, J. J. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.09.005 · Cited by 34
Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010
Harousseau, J. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.076 · Cited by 36
Self-citationMohty, M., Richardson, P. G. G., McCarthy, P. L., & Attal, M. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.83 · Cited by 35
Self-citationMcCarthy, P. L., & Hahn, T. (2013) · Hematology · doi:10.1182/asheducation-2013.1.496 · Cited by 33
Takasu, M., Kondo, S., Akiyama, Y., Takahashi, Y. K., Maeda, S., Baba, Y., Kawase, T., Ichinohe, T., & Awai, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229607 · Cited by 33
Oakervee, H. E., Popat, R., & Cavenagh, J. D. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701540991 · Cited by 33
“By comparison, in one randomized study of thalidomide – dexamethasone versus VAD, 6% and 5% of patients, respectively, did not proceed to stem cell collection because of toxicity [65].”
BackgroundResultInfluentialCheema, P. K., Zadeh, S., Kukreti, V., Reece, D. E., Chen, C. I., Trudel, S., & Mikhael, J. R. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.02.013 · Cited by 35
“Several randomized trials investigating tandem ASCT have shown to improve OS and EFS [35-38], and only 5 patients in this study had received this treatment.”
BackgroundLisenko, K., Pavel, P., Kriegsmann, M., Bruckner, T. M., Hillengaß, J., Goldschmidt, H., Witzens‐Harig, M., Ho, A. D., & Wuchter, P. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.631 · Cited by 33
Autologous stem cell transplantation beyond 60 years of age
Jantunen, E. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705514 · Cited by 35
Mok, T. (2010) · The HKU Scholars Hub (University of Hong Kong) · Cited by 31
Bozdağ, S. C., Yüksel, M. K., & Demirer, T. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_184 · Cited by 33
Cure of myeloma: hype or reality?
Fassas, A., Shaughnessy, J. D., & Barlogie, B. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704757 · Cited by 31
Castagna, L., Magagnoli, M., Balzarotti, M., Sarina, B., Siracusano, L., Nozza, A., Todisco, E., Bramanti, S., Mazza, R., Russo, F., et al. (2006) · American Journal of Hematology · doi:10.1002/ajh.20790 · Cited by 35
“These include sequential HDCT [20,21] or more courses of HDCT [22], as reported for multiple myeloma [23].”
BackgroundInduction Therapy in Multiple Myeloma
Harousseau, J. (2008) · Hematology · doi:10.1182/asheducation-2008.1.306 · Cited by 32
Self-citationNY-ESO-1 immunotherapy for multiple myeloma
Szmania, S. M., Tricot, G. J. K., & van Rhee, F. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600742292 · Cited by 31
Baumann, P., Hagemeier, H., Mandl–Weber, S., Franke, D., & Schmidmaier, R. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328328d18b · Cited by 33
Curability of Multiple Myeloma
Alexanian, R., Delasalle, K. B., Wang, M. L., Thomas, S. K., & Weber, D. (2012) · Bone Marrow Research · doi:10.1155/2012/916479 · Cited by 29
Is there still a role for stem cell transplantation in multiple myeloma?
Mina, R., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32060 · Cited by 32
“In a subgroup analysis, the authors reported that the patients who benefited the most from tandem ASCT were those who failed to achieve a VGPR after the first ASCT, which may be expected because the induction therapy did not include novel agents.(34) In the Italian trial published by Cavo et al,(36) patients undergoin…”
BackgroundAvivi, I. M., Avraham, S., Koren‐Michowitz, M., Zuckerman, T., Aviv, A., Ofran, Y., Benyamini, N., Nagler, A., Rowe, J. M., & Nagler, R. M. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.387 · Cited by 29
Uy, G. L., Goyal, S. D., Fisher, N. M., Oza, A. Y., Tomasson, M. H., Stockerl-Goldstein, K. E., DiPersio, J. F., & Vij, R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.384 · Cited by 30
Pratt, G., Mead, G. P., Godfrey, K. R., Hu, Y., Evans, N. D., Chappell, M. J., Lovell, R., & Bradwell, A. R. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500254216 · Cited by 30
“These 3 patients showing chemosensitivity to high-dose melphalan but incomplete tumor killing may be more likely to benefit from a second autograft procedure [19].”
BackgroundMurakami, H., Handa, H., Abe, M., Iida, S., Ishii, A., Ishikawa, T., Ishida, T., Oota, M., Ozaki, S., Kosaka, M., et al. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00908.x · Cited by 28
“The median overall survival (OS) has been improved by highdose chemotherapy with autologous stem cell transplantation (1).”
BackgroundOutcome of unrelated transplants in patients with multiple myeloma
Ballen, K. K., King, R., Carston, M. J., Kollman, C., Nelson, G. O., Lim, S. H., Reece, D. E., Giralt, S., & Vesole, D. H. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704868 · Cited by 31
Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma
Manochakian, R., Miller, K. C., & Chanan-Khan, A. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-978 · Cited by 32
Brioli, A., Perrone, G., Patriarca, F. F., Pezzi, A., Nobile, F., Ballerini, F., Motta, M. R., Ronconi, S., Tacchetti, P., Catalano, L., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.322 · Cited by 31
Fietz, T. J., Rieger, K., Dimeo, F., Blau, I. W., Thiel, E., & Knauf, W. U. (2004) · Journal of Clinical Apheresis · doi:10.1002/jca.20030 · Cited by 28
Blanes, M., de la Rubia, J., Lahuerta, J. J., González, J. D., Ribas, P., Solano, C., Alegre, A. M., & Sanz, M. Á. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802630170 · Cited by 29
“In our series, the CR/nCR rate was 49% after one ASCT with the ivBU-based conditioning regimen, higher than that previously reported with and oral BU-based regimen [12] and similar to the results reported after double transplantation [23,31], suggesting a high anti-myeloma activity of this conditioning regimen and its…”
BackgroundResultBjörkstrand, B., & Gahrton, G. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.08.010 · Cited by 28
Role of autologous stem-cell transplantation in multiple myeloma
Attal, M., & Harousseau, J. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.09.006 · Cited by 30
Self-citationOutpatient high‐dose melphalan in multiple myeloma patients
Kassar, M., Medoff, E., Seropian, S., & COOPER, D. L. (2006) · Transfusion · doi:10.1111/j.1537-2995.2007.01073.x · Cited by 30
“A recent randomized trial has suggested further incremental improvement after sequential courses of high-dose therapy.(2) These two observations have resulted in multiple myeloma being the most frequent indication for autologous PBPC transplant.”
BackgroundWang, Q., He, F., He, W., Huang, Y., Zeng, J., Zi, F., Zheng, J., Fei, Y., Xu, J., Song, Y., et al. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104342 · Cited by 28
Dhakal, B., Strouse, C. S., D’Souza, A., Arce-Lara, C. E., Esselman, J., Eastwood, D. C., Pasquini, M. C., Saber, W., Drobyski, W. R., Rizzo, J. D., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.08.002 · Cited by 29
Bashir, Q., Khan, H. M., Orlowski, R. Z., Amjad, A. I., Shah, N. D., Parmar, S., Wei, W., Rondón, G., Weber, D. M., Wang, M. L., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22273 · Cited by 28
“These data suggest that RIC allo-HCT can salvage a subset of myeloma patients with relapsed/refractory disease for whom the conventional therapeutic options are otherwise limited [42–44].”
BackgroundSchriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., et al. (2020) · Theranostics · doi:10.7150/thno.38533 · Cited by 29
“Moreover, current treatments are associated with severe side effects [5, 6].”
BackgroundHematological malignancies: disease pathophysiology of leukemic stem cells.
Ramdass, B., Chowdhary, A. S., & Koka, P. S. (2013) · PubMed · Cited by 32
Cure of multiple myeloma – more hype, less reality
Hari, P., Pasquini, M. C., & Vesole, D. H. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705194 · Cited by 32
Mehta, J., & Singhal, S. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705799 · Cited by 29
Majolino, I., Davoli, M., Carnevalli, E., Locasciulli, A., Bartolomeo, P. D., Scimè, R., Corradini, P., Selleri, C., Narni, F., Musso, M., et al. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601186150 · Cited by 29
Treatment of Patients with Multiple Myeloma: An Overview of Systematic Reviews
Kumar, A., Galeb, S., & Djulbegović, B. (2010) · Acta Haematologica · doi:10.1159/000318880 · Cited by 26
“The pooled results from this systematic review showed a statistically non-significant difference between tandem AHCT and single AHCT for the outcome of overall survival (HR 0.89, 95p CI 0.76–1.04; p = 0.16). The event-free survival was significantly better with the use of tandem AHCT (HR 0.79, 95p CI 0.70–0.89; p Harm…”
ResultInfluentialGlauer, J., Pletz, N., Schön, M. P., Schneider, P., Liu, N., Ziegelbauer, K. B., Emmert, S., Wulf, G. G., & Schön, M. P. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.37 · Cited by 30
Shaughnessy, P. J., Chao, N. J. A., Shapiro, J., Walters, K., McCarty, J. M., Abhyankar, S., Shayani, S., Helmons, P. J., Leather, H. L., Pazzalia, A., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.05.008 · Cited by 29
Lisenko, K., Sauer, S., Bruckner, T. M., Egerer, G., Goldschmidt, H., Hillengaß, J., Schmier, J. W., Shah, S., Witzens‐Harig, M., Ho, A. D., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3137-4 · Cited by 29
Smith, V. R., Popat, U., Ciurea, S. O., Nieto, Y. L., Anderlini, P. N., Rondón, G., Alousi, A. M., Qazilbash, M. H., Kebriaei, P., Khouri, I. F., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23499 · Cited by 25
Current therapeutic strategies for multiple myeloma
Torimoto, Y., Shindo, M., Ikuta, K., & Kohgo, Y. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0826-3 · Cited by 27
“Tandem ASCT prolonged event-free survival (EFS) or overall survival (OS), especially for patients who were unable to achieve more than a very good partial response in the initial ASCT [30–32].”
BackgroundProteasome inhibition and its therapeutic potential in multiple myeloma
Chari, A., Mazumder, A., & Jagannath, S. (2010) · Biologics · doi:10.2147/btt.s3419 · Cited by 29
“Two large published phase III studies comparing single vs tandem autologous stem cell transplants in myeloma found that patients who did not achieve a CR/near CR after the first autologus stem cell transplant were the ones that could benefit from a second SCT. 48,49 Therefore, the higher CR rates being obtained with n…”
LEADING ARTICLE International uniform response criteria for multiple myeloma
Durie, B., Harousseau, J., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K. C., Gertz, M. A., Dimopoulos, M. A., Westin, J., Sonneveld, P., et al. (2006) · Cited by 25
Self-citationAutologous stem cell transplantation in multiple myeloma
Ricciuti, G., Falcone, A. P., Cascavilla, N., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04114-2 · Cited by 28
Deol, A., Abrams, J., Masood, A., Al-Kadhimi, Z. S., Abidi, M. H., Ayash, L. J., Lum, L. G., Ratanatharathorn, V., & Uberti, J. P. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.10 · Cited by 26
Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7900 · Cited by 26
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
Michallet, M., Chapuis‐Cellier, C., Dejoie, T., Lombard, C., Caillon, H., Sobh, M. A. K., Moreau, P., Attal, M., & Avet‐Loiseau, H. (2017) · Leukemia · doi:10.1038/leu.2017.209 · Cited by 28
Self-citationOutcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
Garderet, L., Iacobelli, S., Köster, L., Goldschmidt, H., Johansson, J., Bourhis, J. H., Krejčí, M., Leleu, X. P., Potter, M. N., Blaise, D., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.035 · Cited by 27
Self-citationThe potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma
Altenburg, J. D., & Farag, S. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.993753 · Cited by 28
“While high-dose chemotherapy with stem cell support increases the proportion of complete responses, the effect on prolongation of overall survival remains relatively modest, and all patients invariably relapse [1,4-7].”
BackgroundNakasone, H., Kanda, Y., Ueda, T., Matsumoto, K., Shimizu, N., Minami, J., Sakai, R., Hagihara, M., Yokota, A., Oshima, K., et al. (2009) · American Journal of Hematology · doi:10.1002/ajh.21552 · Cited by 28
“Therefore, tandem ASCT may play a less important role in the treatment of MM, because tandem ASCT would not be benefit for those who achieved VGPR after first ASCT [22].”
BackgroundMethodManagement of multiple myeloma: The changing landscape
Reece, D. E. (2007) · Blood Reviews · doi:10.1016/j.blre.2007.07.001 · Cited by 26
Early mortality in multiple myeloma: Experiences from a single institution
Chen, Y.-K., Han, S.-M., Yang, Y., Lin, T.-H., Tzeng, H.-E., Chang, K., Hwang, W., & Teng, C. J. (2016) · Hematology · doi:10.1080/10245332.2015.1101969 · Cited by 26
Kojima, H., Katsuoka, Y., Katsura, Y., Suzuki, S., Suzukawa, K., Hasegawa, Y., & Nagasawa, T. (2006) · International Journal of Hematology · doi:10.1532/ijh97.06067 · Cited by 24
“This strategy was previously demonstrated to be effective for patients with multiple myeloma, especially when adopted in a tandem setting [ 12 ].”
BackgroundInfluentialHussein, M. A., Bolejack, V., Zonder, J. A., Durie, B. G. M., Jakubowiak, A. J., Crowley, J. J., & Barlogie, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9240 · Cited by 24
“Meanwhile, the IFM94 trial confirmed Arkansas phase II pilot data with Total Therapy 1,(3) which demonstrated superior outcomes for tandem compared with single transplantation, although controversy persists about the outcomes.(4) The Arkansas myeloma group then performed a prospective, randomized trial to address the…”
ResultStem-cell transplantation in multiple myeloma: how far have we come?
Soekojo, C. Y., & Kumar, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719888111 · Cited by 27
Clinical and biological features of t(4;14) multiple myeloma: a prospective study
Karlin, L., Soulier, J., Chandesris, M., Choquet, S., Belhadj, K., Macro, M., Bouscary, D., Porcher, R., Ghez, D., Malphettes, M., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.537795 · Cited by 27
“The overall RR (ORR) of our patients treated with HDT is quite similar to the usually reported ORR of high-dose-treated patients with MM without t(4;14) [17].”
ResultRole of Stem Cell Transplantation
Harousseau, J. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.001 · Cited by 30
Self-citationAn elective single autograft with high-dose melphalan: single-center study of 451 patients
Sirohi, B., Powles, R., Mehta, J., Rudin, C. M., Kulkarni, S., Horton, C., Saso, R. M., Singhal, S., & Treleaven, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705000 · Cited by 24
Autologous hematopoietic cell transplantation: An update for clinicians
Hamadani, M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.952662 · Cited by 27
History of Hematopoietic Stem Cell Transplantation
Ezzone, S. A. (2009) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2009.03.004 · Cited by 23
Kröger, N. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404775 · Cited by 23
Park, D. S., Akuffo, A. A., Muench, D. E., Grimes, H. L., Epling‐Burnette, P. K., Maini, P. K., Anderson, A. R. A., & Bonsall, M. B. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006913 · Cited by 25
Using Genomics to Identify High-Risk Myeloma after Autologous Stem Cell Transplantation
Shaughnessy, J. D., & Barlogie, B. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.10.002 · Cited by 23
Advances in biology and treatment of multiple myeloma
Ludwig, H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi717 · Cited by 23
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Martino, M. V., Olivieri, A., Offidani, M., Vigna, E., Moscato, T., Fedele, R., Montanari, M., Console, G., Gentile, M., Messina, G., et al. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.788643 · Cited by 23
“The tandem auto-HPCT approach achieved improvement in OS [39], even though a survival benefit was mainly seen in those patients who failed to achieve at least a very good partial remission, as defined by the European Group for Blood and Marrow Transplantation (EBMT) [40,41].”
BackgroundPerspectives in the treatment of multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Lucia, E., Vigna, E., & Morabito, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.799132 · Cited by 25
“The benefit of tandem versus single ASCT has been questioned [96,97].”
BackgroundMahtouk, K., Hose, D., Vos, J. D., Moreaux, J., Jourdan, M., Rossi, J. F., Reme, T. X., Goldschmidt, H., & Klein, B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1758 · Cited by 23
Multiple Myeloma in the Very Old: An IASIA Conference Report
Tuchman, S. A., Shapiro, G. R., Ershler, W. B., Badros, A. Z., Cohen, H. J., Dispenzieri, A. A., Flores, I. Q., Kanapuru, B., Jurivich, D. A., Longo, D. L., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju067 · Cited by 22
Cytomegalovirus: an unlikely ally in the fight against blood cancers?
Bigley, A. B., Baker, F. L., & Simpson, R. J. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13152 · Cited by 22
The challenges of checkpoint inhibition in the treatment of multiple myeloma
Paul, B. A., Kang, S., Zheng, Z., & Kang, Y. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.10.003 · Cited by 24
Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
Biran, N., Jagannath, S., & Chari, A. (2013) · PubMed · Cited by 25
Immunotherapy of multiple myeloma: the start of a long and tortuous journey
Harrison, S. J., Cook, G., Nibbs, R. J. B., & Prince, H. M. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.12.1769 · Cited by 22
Thalidomide and lenalidomide in multiple myeloma
Mazumder, A., & Jagannath, S. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.06.006 · Cited by 23
Stem cell transplantation for multiple myeloma
Kumar, S. K. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328324bc04 · Cited by 25
Martino, M. V., Montanari, M., Bruno, B., Console, G., Irrera, G., Messina, G., Offidani, M., Scortechini, I., Moscato, T., Fedele, R., et al. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707185 · Cited by 22
“The tandem AHPCT approach achieved improvement in OS [18,19] even though a survival benefit was mainly seen in patients who failed to achieve at least very good partial remission as defined by the European Group for Blood and Marrow Transplantation [20,21].”
Hayden, P. J., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f0e948 · Cited by 25
Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Pant, S., & Copelan, E. A. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.05.002 · Cited by 22
Long-Term Follow-Up of Tandem Autologous Stem-Cell Transplantation in Multiple Myeloma
Regelink, J. C., van Roessel, C., van Galen, K. P. M., Ossenkoppele, G. J., Huijgens, P. C., & Zweegman, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5515 · Cited by 22
Samaras, P., Pfrommer, S., Seifert, B., Petrausch, U., Mischo, A., Schmidt, A., Schanz, U., Nair, G., Bargetzi, M. J., Taverna, C., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.020 · Cited by 21
Melphalan: old and new uses of a still master drug for multiple myeloma
Musto, P., & D’Auria, F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.9.1467 · Cited by 21
“conducted a randomized trial (IFM-94) comparing single and double ASCT [82] .”
MethodLefrère, F., Zohar, S., Ghez, D., Delarue, R., Audat, F., Suárez, F., Hermine, O., Damaj, G. L., Maillard, N., Ribeil, J., et al. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705308 · Cited by 21
Gupta, S., Zhou, P. H., Hassoun, H., Kewalramani, T., REICH, L. M., Costello, S., Drake, L., Klimek, V. M., Dhodapkar, M. V., Teruya‐Feldstein, J., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704779 · Cited by 21
Wallington-Beddoe, C. T., Gottlieb, D. J., Garvin, F., Antonenas, V., & Sartor, M. M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.06.018 · Cited by 21
Iacobelli, S., de Wreede, L. C., Schönland, S. O., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A. M., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.310 · Cited by 21
BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma
Talamo, G., Claxton, D. F., Dougherty, D. W., Ehmann, C. W., Sivik, J. M., Drabick, J. J., & Rybka, W. B. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.446 · Cited by 22
Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., & Kumar, S. K. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.3.343 · Cited by 24
PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
Ueno, S., Tatetsu, H., Hata, H., Iino, T., Niiro, H., Akashi, K., Tenen, D. G., Mitsuya, H., & Okuno, Y. (2009) · Oncogene · doi:10.1038/onc.2009.263 · Cited by 20
“Multiple myeloma is an incurable hematological malignancy that is resistant to several chemotherapeutic agents as well as hematopoietic stem cell transplantation (Attal et al., 2003).”
Background
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.